- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01163773
Milk Consumption and the Metabolic Syndrome in Menopausal Women (MILK)
Cardiovascular disease (CVD) represents the first cause of mortality in industrialized countries such as Canada and the United States. In that regard, it is being increasingly recognized that a significant proportion of CVD events may be attributable to the presence of a cluster of metabolic and physiological perturbations defined as the metabolic syndrome (MetS). The National Cholesterol Education Program- Adult Treatment Panel III (NCEP-ATP III) has recently proposed a clinical definition to identify individuals with the MetS. This definition is based on the presence of at least three of the following five characteristics: 1- abdominal obesity, 2- hypertriglyceridemia, 3- reduced plasma HDL-C levels, 4- high blood pressure, 5- high fasting blood glucose levels. Recent data have suggested that the MetS based on this definition was associated with a 2 to 5 fold increase in the risk of CVD in men as well as in women. These are alarming figures since it has been suggested that as much as 35 to 45% of female aged > 65 years in the US may have the MetS. It is therefore imperative to develop new preventive strategies that will be efficacious in attenuating the impact of the MetS on the progressing rates of CVD in women. In that context, there is accumulating evidence to suggest that milk and dairy products may beneficially modify several components of the MetS. However, most of the available data to date are based on observational studies or interventional studies with minimal nutritional control. Thus, metabolically controlled studies that document the impact of milk consumption on cardiovascular risk factors associated with the MetS in women defined a priori as having the MetS are utterly lacking.
The purpose of this study was to investigate the impact of milk consumption on features of the MetS in menopausal women presenting one or more features of the MetS.
Přehled studie
Detailní popis
The proposed research will be undertaken as a randomized, cross-over, nutritionally controlled study, with participants being subjected to two 6-week isocaloric diets separated by a 4-week washout period. No stratification was considered since the population recruited will be relatively homogeneous. The experimental diet (designed as 'Milk') will be formulated so that the percentage of daily calories from fat (30%), saturated fat (10%), carbohydrates (55%) and proteins (15%) will conform to most of the dietary recommendations of the American Heart Association and the NCEP for primary prevention of CVD, with the exception of saturated fats (slight excess) and fibers (slight deficit). The cholesterol content of the experimental diet will not exceed 200 mg/day. The only source of dairy products during the experimental phase will be from 2% fat milk. We have chosen to use 2% fat milk because this is the most frequently consumed dairy product in Canada. Two percent fat milk also goes through minimal processing compared to milk or to other dairy products such as yogurt and cheese. Thus, bioactive components in milk are more likely to be retained in the 2% fat milk than in other more extensively processed products. The energy intake from milk will represent 20% of the consumed kcal/day. Based on a reasonable 2000 kcal/day regimen, a 20% intake attributable to 2% fat milk will correspond to 400 day/kcal, which will be derived from a 'daily dose' of 3 portions of milk/day. This dose has been shown to be effective in previous uncontrolled studies. The Control diet will be virtually identical in terms of menus, calories and macronutrient composition, with the exception that milk will be formally excluded from the regimen. The energy intake and changes in macronutrient composition attributable to the milk component in the experimental diet will be compensated in the control diet by modifying the protein, carbohydrate and lipid component of the various recipes.
A 4-week stabilization run-in period will precede the randomization of participants. During this run-in period, participants will be asked and instructed to comply to the NCEP-ATP III prudent diet. They will be asked to maintain their body weight constant during this period. Milk consumption will be adapted during this period to comply to the recommendations of NCEP-ATP III. The washout period between the two experimental diets will last 4 weeks and will also consist of NCEP-ATP III recommended diet. It must be stressed that foods will not be provided during the run-in and wash-out periods. These periods are imposed to minimize the inter- and intra-individual variability before and between the experimental phases.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Quebec, Kanada, G1V 0A6
- Institute of Nutraceutical and Functional Foods (INAF), Laval University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Menopausal women (absence of menses > 12 months and FSH > 40 IU/ml), aged between 45 and 65 years
- Presenting 1 or more features of the MetS based on the NCEP-ATP III definition
- Average consumption of milk/dairy products fewer than 2 portions/d (≤ 1.9)
- Stable body weight (+/- 2 kg) for 6 months before the beginning of the study
Exclusion Criteria:
- Previous history of cardiovascular disease, type 2 diabetes and monogenic dyslipidemia
- Subjects taking medications for hyperlipidemia, hypertension or hormonal replacement therapy
- Endocrine disorders
- Smoking
- Food allergies, milk aversion or intolerant to lactose
- Women with extreme nutritional habits such as vegetarism or alcohol consumption > 2 drinks/day
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Crossover Assignment
- Maskování: Žádné (otevřený štítek)
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Plasma TG levels (MetS criteria)
Časové okno: At the beginning and the end of the two 6-week diets
|
At the beginning and the end of the two 6-week diets
|
|
HDL-C levels (MetS criteria)
Časové okno: At the beginning and the end of the two 6-week diets
|
At the beginning and the end of the two 6-week diets
|
|
Systolic and diastolic blood pressure (MetS criteria)
Časové okno: At the beginning and the end of the two 6-week diets
|
At the beginning and the end of the two 6-week diets
|
|
Fasting blood glucose (MetS criteria)
Časové okno: At the beginning and the end of the two 6-week diets
|
At the beginning and the end of the two 6-week diets
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Anthropometric measures (waist and hip circumferences)
Časové okno: At the beginning and the end of the two 6-week diets
|
At the beginning and the end of the two 6-week diets
|
|
LDL and HDL particle size
Časové okno: At the beginning and the end of the two 6-week diets
|
At the beginning and the end of the two 6-week diets
|
|
Markers of the oxidative stress (i.e. oxLDL and 8-iso-PGF2a levels)
Časové okno: At the beginning and the end of the two 6-week diets
|
At the beginning and the end of the two 6-week diets
|
|
Markers of a pro-inflammatory state (i.e. C-reactive protein and IL-6 levels)
Časové okno: At the beginning and the end of the two 6-week diets
|
At the beginning and the end of the two 6-week diets
|
|
Surrogates of cholesterol absorption and synthesis
Časové okno: At the beginning and the end of the two 6-week diets
|
At the beginning and the end of the two 6-week diets
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Benoît Lamarche, PhD, Institute of Nutraceutical and Functional Foods (INAF), Laval University
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- INAF-2004-039
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na MILK
-
University of PittsburghNational Institute of Nursing Research (NINR)Dokončeno
-
Loma Linda UniversityDokončenoPředčasný porod | Postnatální omezení růstu | Kolekce mateřského mlékaSpojené státy
-
St. Louis UniversityDokončenoPředčasný porod novorozence | Lidské mlékoSpojené státy
-
Loyola UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... a další spolupracovníciNáborNemluvně, nedonošené, NemociSpojené státy
-
Loyola UniversityDokončenoStres | Vývoj kojencůSpojené státy
-
KK Women's and Children's HospitalAktivní, ne náborSelhání růstu | Dítě s velmi nízkou porodní hmotností | Dárcovské mateřské mlékoSingapur
-
NEOCOSURNeznámýZrychlení růstuChile
-
Inner Mongolia Yili Industrial Group Co., LtdDokončenoNachlazení | Lidská chřipka | ImunizaceČína
-
Huilian ZhuZatím nenabíráme